Pulmatrix Announces Grant of Patent Supporting Its Novel Pulmonary Drug Therapies

Granted New European Patent Encompasses Compositions and Use of PUR118 for Treatment of COPD, CF and Other Respiratory Diseases

LEXINGTON, Mass.--(BUSINESS WIRE)-- Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced that the European Patent Office has granted Pulmatrix’s patent number EP 2315580 B1 entitled “Pharmaceutical formulations and methods for treating respiratory tract infections”, a patent relating to compositions and uses of the company’s inhaled drug therapies. The newly-granted patent describes both dry powder and liquid formulations with optimized ranges of the formulation components, and also describes methods for treating respiratory infections and diseases as well as methods for treating acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). The granted patent also specifically contains composition of matter claims covering Pulmatrix’s lead dry powder iCALM formulation, PUR118, which is being evaluated in ongoing clinical trials, including two on-going Phase 1b studies in patients with COPD which includes patients with emphysema and chronic bronchitis.

“We are pleased that our proprietary technology has been recognized by the European Patent Office, both for its unique formulations as well as its methods of use in treating respiratory diseases and infections,” said Robert Connelly, Chief Executive Officer of Pulmatrix. “With composition of matter claims from this grant and other granted patents, we are very confident that our full intellectual property portfolio will protect our iCALM and iSPERSE platforms for delivering both standalone and combination therapies that could offer significant unique benefits to patients.”

Pulmatrix has built a comprehensive intellectual property portfolio to support the advancement of the company’s novel inhaled drug platforms, iCALM and iSPERSE. Pulmatrix’s intellectual property estate includes 7 granted patents and over 100 pending applications worldwide. This broad intellectual property covers compositions of both iCALM and iSPERSE formulations, including multi-drug formulations, as well as the specific application of iCALM and iSPERSE products to a number of chronic and serious respiratory diseases, such as COPD, CF, asthma, respiratory infections, bronchiectasis and other respiratory diseases. Relevant multi-drug combinations covered in the intellectual property include, but are not limited to, one or more of the following classes of inhaled therapeutics: long-acting muscarinic antagonists (LAMAs), long-acting beta-2 agonists (LABAs), short acting beta agonists (SABAs), inhaled corticosteroids (ICS) and antibiotics.

About Pulmatrix

Pulmatrix, Inc. is a clinical stage biotechnology company developing two novel pulmonary drug platforms, iCALM™ and iSPERSE™, for the prevention, treatment and control of respiratory diseases. iCALM (inhaled cationic airway lining modulators) are first-of-a-kind inhaled therapies to prevent and treat acute exacerbations and improve lung function in patients with chronic respiratory diseases, such as COPD, asthma, cystic fibrosis, idiopathic pulmonary fibrosis (IPF) and bronchiectasis, while also treating and preventing respiratory infections including influenza, ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV). iSPERSE (inhaled small particles easily respirable and emittable) is a proprietary dry powder drug delivery platform, comprised of small, dense particles with unique capabilities to support efficient, reproducible lung delivery of a broad spectrum of drug classes from small molecule to macromolecule including double- and triple-combination therapies. Pulmatrix’s lead iCALM clinical candidate, PUR118, is in two on-going Phase 1b studies in patients with COPD. The Company is pursuing both proprietary and partnered applications for iCALM and iSPERSE. For additional information about Pulmatrix, please visit http://www.pulmatrix.com.

iCALM™ and iSPERSE™ are trademarks of Pulmatrix, Inc.



CONTACT:

The Yates Network
Kathryn Morris, 845-635-9828
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.